Adolor cut to sector perform by RBC

Adolor Corp. was downgraded to a sector perform, above average risk rating from outperform by RBC Capital Markets analyst Michael Yee. The analyst based the downgraded rating on serious cardiovascular safety concerns raised by the Food and Drug Administration for alvimopan as well as commercial viability given the potential unfavorable risk benefit ratio. Yee doesn't see any meaningful catalysts for the stock until the first half of 2007. Shares of the Exton, Pa.-based biopharmaceutical company were down $6.25, or 44.84%, at $7.69. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.